In Authorized Generic Spree, Daiichi Sankyo Espha Focuses More on “Popularization” than “Sales” When It Comes to Cancer AGs

April 24, 2019
Hiroto Yoshiwaka Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its growth, with the country’s volume-based generic utilization rate expected to reach 80% next year. However, room for a...read more